The new multi-purpose facility will be able to produce sterile liquid vaccines and medicines and will also include an R&D pilot plant to manufacture medicines for clinical trials. Additionally, GSK intends to establish a new vaccines drug substance facility at the site, dedicated to manufacturing products based on the company’s novel MAPS technology, subsequent to future regulatory submissions and approvals. The planned expansion will double the size and capacity of the Marietta site.

Regis Simard, president Global Supply Chain, GSK, said: This landmark investment will establish Marietta as an innovation and manufacturing hub capable of delivering next-generation medicines and vaccines to people around the world. We’re grateful for the support of local and state officials, who made this project possible, and we are excited to expand upon the important work already underway at the Marietta site.”

Construction of the new facilities is expected to start by the end of this year. According to GSK, the drug substance facility is anticipated to be operational by the end of 2027, with the drug product facility following by the end of 2028.